The Sustained Release Excipients Market is experiencing a growth spurt, fueled by the increasing demand for long-acting medications. A recent industry analysis reveals a promising outlook, with the market valued at a substantial US$1,198.69 million in 2022. Looking ahead, the market is projected to climb at a robust Compound Annual Growth Rate (CAGR) of 7.5%, reaching an estimated US$1.8 billion by 2032.
The sustained release excipients market has historically been characterized by regional manufacturers vying for market share, primarily through competitive pricing strategies. This fragmentation has affected the profitability of companies operating within the sector. However, a shift is occurring due to an enhanced understanding of sustained release excipients and the limitations related to test specificity and sensitivity for locally produced sustained release excipients.
Companies like BASF Corporation, Ashland Global Holdings Inc., and Dow Chemical Company generate more than 42.8% of the market’s revenue for sustained release excipients globally. The businesses involved in this industry are collaborating with local distributors to increase the penetration of their products in the sustained release excipients market.
Research identifies the largest revenue shareholding categories in the sustained release excipients marketplace based on product type, end-user, and route of administration.
- Polymer is currently the largest product type category worth US$ 300 Million, whereas gelatin represents the most opportunistic one.
- While the oral route of administration remains highly sought after, injectable is presumed to gradually take over.
- Biopharmaceutical companies and CMOs pose fierce competition to pharmaceutical companies – the dominant end-user of sustained-release excipients.
“The top five players leading the competition in the global sustained release excipients landscape account for a collective revenue share of over 50%, whereas several relatively small companies represent the rest. A majority of competitors have a limited offering portfolio and significantly depend on product differentiation for an edge in niche treatment areas,” explains a senior research analyst. “Product innovation and market expansion have been the top developmental strategies of companies so far, which are now complemented with strategic partnerships,” the analyst adds further.
Multi-level Partnerships – The Key to Delivering Top-Notch Excipient Formulations
FMI underlines the critical role of strategic collaborations – between formulators of sustained release excipients and stakeholders across the value chain – in shaping the growth of brands as well as the entire sustained release excipients ecosystem.
While partnerships are expected to prominently focus on spotting the key challenges facing manufacturers, continued education about functionality, variability, and consistency of sustained release excipients is also an important objective. Drug product manufacturers working in tandem with formulators of sustained-release excipients are helping companies deliver best-in-class solutions addressing the most prominent pull factors associated with sustained-release excipients.
To best grasp real-time market needs, sustained-release excipient formulators are most likely to strengthen interaction with end-user customers. This move offers a dual advantage as a developmental strategy – by helping manufacturers precisely understand and address the challenges facing pharmaceutical markets and stimulating the development of new excipient formulations that tap into evolving needs.
A recent deal (2017) involving the combination of The Dow Chemical Company-DuPont-FMC (Health & Nutrition) has been a classic example of a collaborative operation, involving channel partners as well as customers.
Additional Questions Answered
Some of the additional questions addressed in this report on the Global Sustained Release Excipients Industry-
- What is the revenue potential of the sustained release excipients market across regions of North America and Europe?
- Who are the key competitors and what are their portfolios in the sustained release excipients market?
- What are the major challenges influencing the growth of the sustained-release excipients market?
- How intervention from regulatory authority is shaping the sustained release excipients market growth?
Sustained Release Excipients Market Competitive Landscape:
The competition section of the sustained release excipients market features profiles of key players operating in the industry based on their market shares, differential strategies, product offerings, marketing approach, and company dashboards. Examples of some of the key players featured in this report include FMC Corporation, Ashland Global Holdings, BASF Corporation, The Dow Chemical Company, Roquette Freres S.A. Colorcon Inc., and Croda International Inc.
Sustained Release Excipients Market Segmentation:
The report offers a comprehensive taxonomy of the sustained release excipients market based on product type, end-user, route of administration route, and region. The sustained-release excipients are sold for various types of test samples, such as blood, skin, etc. These sustained-release excipients are used by pharmaceutical companies, biopharmaceutical companies, and neutraceutical companies, and for various types of sustained-release excipients, such as food allergies, drug allergies, latex allergies, and other types of allergies.
End-use segments in the sustained release excipients market which are a part of this sustained release excipients Industry report include pharmaceutical companies, biopharmaceutical companies, and other end users, such as nutraceutical manufacturers and contract manufacturing organizations. The sustained release excipients market has been analyzed across regions of North America, Latin America, Europe, CIS & Russia, Asia Pacific, and MEA.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
